Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $87.84 USD
Change Today +0.38 / 0.43%
Volume 1.0M
HSP On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

hospira inc (HSP) Key Developments

Hospira, Inc. Announces Availability of INFLECTRA™ (Infliximab) in Canada

Hospira Inc. announced the availability of INFLECTRA™ (infliximab) in Canada. Approved by Health Canada, INFLECTRA is available to healthcare practitioners for the treatment of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and plaque psoriasis. INFLECTRA is biosimilar to the reference product REMICADE® (infliximab).

Clinigen Group Plc Extends Foscavir U.S Distribution Contract with Hospira, Inc

Clinigen Group Plc announced the extension and renegotiation of the exclusive license and distribution agreement with Hospira Inc. for its anti-viral product Foscavir (foscarnet sodium) in the U.S. This is expected to be beneficial to both parties. The original distribution agreement with Hospira established in July 2011 was due to expire in May 2017. The new agreement is for five years extending the term to 31 December 2019.

Hospira Launches Remicade Biosimilar Inflectra in Additional European Countries

Hospira announced that it is launching its Remicade biosimilar Inflectra in at least 10 new European markets, nearly doubling the product's presence on the continent. Inflectra (infliximab) is the first biosimilar monoclonal antibody to be marketed in Europe, will soon be available in Austria, Sweden, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands and Spain. Inflectra mimics Janssen's Remicade (infliximab), which treats inflammatory diseases such as psoriatic and rheumatoid arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, plaque psoriasis and ulcerative colitis.

Hospira Posts Interim Results from Patient Registry for Biosimilar Inflectra in IBD Treatment

Hospira (US) presented interim results from a patient registry study at the European Crohn's and Colitis Organisation's conference on inflammatory bowel diseases (IBDs) in Barcelona, Spain, on 19 February. The study looked at the firm's biosimilar version of Remicade (infliximab; Johnson & Johnson; J&J, US), Inflectra. The results from the ongoing independent, prospective study conducted in 90 patients across Hungary demonstrated comparable efficacy between Inflectra and Remicade for inducing and maintaining remission of Crohn's disease (CD) and ulcerative colitis (UC). So far, the patients who were treated with Inflectra for either CD (57) or UC (33) demonstrated reductions in disease activity at two and six weeks post treatment. Levels of C-reactive protein, a marker for inflammation, also declined in UC patients. With regards to safety and tolerability, Hospira reports that 4 of the 90 patients had an allergic reaction to Inflectra. The four patients have previously received anti- tumour necrosis factor treatment. The registry trial will continue to enrol patients and will follow CD patients for 108 weeks and UC patients for 54 weeks in order to assess the safety, adherence, long-term outcomes, and the cost of treatment with Inflectra.

Shareholders Foundation Announces Investor Lawsuit Against Acquisition of Hospira, Inc

The Shareholders Foundation Inc. announced that an investor, who currently holds shares of Hospira Inc., filed a lawsuit in effort to stop the proposed takeover of Hospira Inc. by Pfizer for $90 per share. The plaintiff alleges that the defendants breached their fiduciary duties owed to stockholders by agreeing to sell Hospira Inc. too cheaply via an unfair process to Pfizer Inc. On February 5, 2015, Pfizer Inc. and Hospira Inc. announced that they have entered into a merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion. However, the plaintiff claims that the $90-offer is too low and undervalues Hospira Inc. In addition, the plaintiff claims that the process is also unfair to stockholders.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSP:US $87.84 USD +0.38

HSP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chugai Pharmaceutical Co Ltd ¥3,760 JPY +75.00
Cintas Corp $81.74 USD +0.36
Mallinckrodt PLC $123.12 USD +0.74
UCB SA €69.71 EUR +0.74
Zimmer Holdings Inc $115.92 USD +1.31
View Industry Companies
 

Industry Analysis

HSP

Industry Average

Valuation HSP Industry Range
Price/Earnings 44.8x
Price/Sales 3.3x
Price/Book 4.5x
Price/Cash Flow 45.2x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOSPIRA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.